Glutathione and the Liver: What Human Studies Report
Glutathione is a cysteine-containing tripeptide that is concentrated in liver cells and tied to enzymes such as gamma-glutamyltransferase, glutathione S-transferases and the selenium-dependent glutathione peroxidases. The human literature gathered here is mostly about markers and about other supplements studied in fatty liver populations, not about oral glutathione as a liver treatment. In the United States oral glutathione is sold as a dietary supplement, a category the FDA does not approve for efficacy before sale. No glutathione product has FDA approval for skin lightening.
Glutathione is a three amino acid molecule built from glutamate, cysteine and glycine, and the liver is one of the organs where it is most concentrated and most actively turned over. That anatomical fact is the reason the phrase "glutathione and liver health" appears so often. What the published human literature actually contains is narrower than the phrase suggests, and this page separates the biology, the clinical trial record in liver conditions, and the regulatory status of the products sold in the United States.
For a plain definition of the molecule, see the glutathione glossary entry. For the broader overview of contexts in which it has been studied, see what is glutathione used for and how does glutathione work. This page does not repeat that material.
Hepatic glutathione biology in brief
Three enzyme families connect glutathione to liver measurement and liver disease research. The first is gamma-glutamyltransferase, the enzyme that cleaves the gamma-glutamyl bond of extracellular glutathione and that also appears on routine liver panels; a 2016 review in Liver International examined gamma-glutamyltransferase both as a participant in glutathione handling and as a circulating marker whose elevation has been linked to liver and cardiometabolic outcomes (PMID 27512925). That dual role is why a raised enzyme value on a laboratory report is not a direct readout of how much glutathione a liver holds.
The second family is the glutathione S-transferases, which conjugate glutathione to electrophilic compounds. A 2022 Journal of Hepatology report described hepatocyte glutathione S-transferase mu 2 as suppressing ASK1 signalling and thereby limiting non-alcoholic steatohepatitis in experimental models, which places a glutathione-dependent enzyme inside a stress-kinase pathway rather than in a simple antioxidant role (PMID 34656650). The third family is the glutathione peroxidases, which are selenoproteins; a 2020 review in Hormones examined selenium and selenoprotein P in non-alcoholic fatty liver disease and discussed how selenium status intersects with this antioxidant system in liver disease (PMID 31493247).
None of those mechanistic observations establishes that swallowing glutathione changes any of those enzyme systems in a person. Mechanism and clinical effect are separate questions, and the sections below keep them separate.
What the cited human literature does and does not cover
The verified papers assembled for this page are drawn from fatty liver research. They include a randomised controlled trial of curcumin (PMID 40573083), a human study of combined metabolic activators containing NAD+ precursors (PMID 37271226), supplementation studies of grape seed extract (PMID 38419408) and of alpha-tocopherol with ascorbic acid added to statin therapy (PMID 29887885), a systematic review of inositol (PMID 33153126), a review of L-ornithine L-aspartate (PMID 30016770), an observational case-cohort analysis of adiposity and metabolomic biomarkers (PMID 34902008) and a 2024 review chapter on fatty liver disease and fibrosis staging (PMID 39287864).
What this set does not contain is a randomised trial of oral glutathione as a treatment for a liver disease. That absence is the single most important fact on this page. Readers encountering confident claims that glutathione reverses fatty liver should ask which trial, in which population, against which comparator, and with which endpoint. The records below are summarised for exactly that reason: they show the shape of the supplementation literature in fatty liver populations without attributing any of it to glutathione itself.
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeHuman and clinical records in liver conditions
| Record | Population or scope | Design and comparator | Endpoint focus | What the record reports |
|---|---|---|---|---|
| PMID 40573083 | Adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease | Randomised controlled trial with a control arm | Inflammation control | Researchers tested curcumin rather than glutathione; the trial record is about inflammatory endpoints in this combined metabolic population |
| PMID 37271226 | Human participants receiving combined metabolic activators | Acute-effect comparison of different NAD+ precursors within the combination | Acute metabolic response to the precursor component | The study compared NAD+ precursors inside a multi-ingredient formulation, so single-ingredient attribution is not possible |
| PMID 38419408 | People with non-alcoholic fatty liver disease | Supplementation study of grape seed extract | Liver-related and metabolic measures in fatty liver | A polyphenol supplement was the intervention; the record does not evaluate glutathione supplementation |
| PMID 29887885 | Men with non-alcoholic fatty liver disease already on statin therapy | Vitamin supplementation added to existing statin treatment | Effect of adding alpha-tocopherol and ascorbic acid | The design tested antioxidant vitamins as an add-on, not glutathione, and the population was limited to men |
| PMID 33153126 | Published studies of inositol in fatty liver disease | Systematic review of deficiency and supplementation reports | Inositol status and supplementation outcomes | Researchers synthesised a heterogeneous literature; the review concerns inositol only |
| PMID 30016770 | Non-alcoholic fatty liver disease | Review of L-ornithine L-aspartate evidence | Hepatoprotective endpoints | An amino acid compound unrelated to glutathione supplementation is the subject |
| PMID 34902008 | Cohort participants followed for incident fatty liver disease | Observational case-cohort analysis, no intervention | Adiposity and metabolomic biomarkers as risk correlates | Associations only; an observational design cannot show that changing a biomarker changes disease risk |
| PMID 39287864 | Fatty liver disease and fibrosis | Review chapter | Staging of hepatic fibrosis | Background on how fibrosis severity is assessed, which is the context any supplementation claim has to be judged against |
Read together, those records describe a research field that tests many candidate supplements in fatty liver populations, uses varied endpoints, and often enrols small or narrowly defined groups such as men already taking statins (PMID 29887885) or people with both diabetes and steatotic liver disease (PMID 40573083). Generalising from any one of them to a different compound, including glutathione, is not supported.
Animal work is not a substitute
Preclinical studies in rodents frequently report changes in hepatic antioxidant measures. A 2022 study in the Journal of Food Biochemistry reported that zingerone improved features of non-alcoholic fatty liver disease in rats through AMPK activation (PMID 35338494). Rodent results of that kind describe a mechanism in an animal model and do not establish an outcome in people, which is why this page keeps animal and human evidence in separate sections.
Liver enzymes, biomarkers and what they can show
Gamma-glutamyltransferase illustrates the interpretation problem well. Because the enzyme sits in the pathway that breaks down extracellular glutathione, it is sometimes described as an oxidative stress marker, but the 2016 review treated it as a measure with multiple drivers and debated clinical meaning rather than as a clean index of antioxidant status (PMID 27512925). Metabolomic panels raise a similar issue: the 2022 case-cohort analysis linked adiposity and circulating metabolomic biomarkers to incident fatty liver disease, but the authors examined risk associations in an observational framework (PMID 34902008).
Disease staging adds a further layer. The 2024 review chapter on fatty liver disease covered how hepatic fibrosis is staged, which matters because a biomarker shift and a change in fibrosis stage are not interchangeable endpoints (PMID 39287864).
Tracking research? Log entries with dates, lots and notes: records, never plans.
Get the appSafety and adverse events in the cited set: What Studies Report
The verified records collected here were not trials of glutathione supplementation, so they contribute no adverse-event data on oral glutathione in liver disease. The interventions studied were curcumin in a randomised trial (PMID 40573083), combined metabolic activators containing NAD+ precursors (PMID 37271226), grape seed extract (PMID 38419408), antioxidant vitamins alongside statin therapy (PMID 29887885) and L-ornithine L-aspartate (PMID 30016770). Absence of adverse-event data in a citation set is not evidence of safety; it means the question was not asked in these papers. Questions about interactions with prescribed liver medication belong with a treating clinician, not with a web page.
Regulatory status in the United States
Oral glutathione is marketed in the United States as a dietary supplement. The FDA does not approve dietary supplements for efficacy before they are sold, and manufacturers are responsible for the safety and labelling of their products; a supplement appearing on a shelf therefore carries no agency finding that it works for the liver or for anything else. That category status should be kept entirely separate from prescription medicines and from intravenous administration, which appear in the research literature only as study designs or as the subject of regulatory warnings. No glutathione product has FDA approval for skin lightening.
This page is for educational purposes only and is not medical advice; consult a licensed physician about liver test results, suspected liver disease, or any supplement taken alongside prescribed treatment.
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeLimits readers should carry away
- No direct trial evidence here. The verified literature set contains no randomised trial of oral glutathione in a liver disease population; the supplementation trials cited tested other compounds (PMID 40573083, PMID 38419408).
- Mechanism is not outcome. Enzyme-level findings on glutathione S-transferase mu 2 came from experimental models of steatohepatitis (PMID 34656650).
- Markers are indirect. Gamma-glutamyltransferase has several drivers and was reviewed as a contested marker rather than a glutathione gauge (PMID 27512925).
- Nutrient status complicates the picture. Selenium supports glutathione peroxidases, and selenium and selenoprotein P were reviewed specifically in fatty liver disease (PMID 31493247).
- Observational data do not prove causation. The metabolomic case-cohort analysis reported associations with incident disease (PMID 34902008).
- Multi-ingredient formulations hide attribution. The combined metabolic activator study compared precursors inside a combination product (PMID 37271226).
Related reading on PeptideU
References
- Nonalcoholic Fatty Liver Disease and Staging of Hepatic Fibrosis (Advances in Experimental Medicine and Biology, 2024)
- Curcumin for Inflammation Control in Individuals with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial (Nutrients, 2025)
- The acute effect of different NAD+ precursors included in the combined metabolic activators (Free Radical Biology and Medicine, 2023)
- Selenium and selenoprotein P in nonalcoholic fatty liver disease (Hormones, 2020)
- Adiposity, metabolomic biomarkers, and risk of nonalcoholic fatty liver disease: a case-cohort study (The American Journal of Clinical Nutrition, 2022)
- Zingerone ameliorates non-alcoholic fatty liver disease in rats by activating AMPK (Journal of Food Biochemistry, 2022)
- Gamma-glutamyltransferase, friend or foe within? (Liver International, 2016)
- Grape seed extract supplementation in non-alcoholic fatty liver disease (International Journal for Vitamin and Nutrition Research, 2024)
- Hepatocyte glutathione S-transferase mu 2 prevents non-alcoholic steatohepatitis by suppressing ASK1 signaling (Journal of Hepatology, 2022)
- Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease (Digestive Diseases, 2019)
- Inositol and Non-Alcoholic Fatty Liver Disease: A Systematic Review on Deficiencies and Supplementation (Nutrients, 2020)
- Supplementation with Alpha-Tocopherol and Ascorbic Acid to Nonalcoholic Fatty Liver Disease's Statin Therapy in Men (Advances in Pharmacological Sciences, 2018)
Frequently asked questions
Do human trials show that oral glutathione treats fatty liver disease?▾
The verified literature summarised on this page contains no randomised trial of oral glutathione in a liver disease population. The supplementation trials cited tested other compounds, such as curcumin in people with type 2 diabetes and steatotic liver disease (PMID 40573083) and grape seed extract in non-alcoholic fatty liver disease (PMID 38419408). Those records cannot be read as evidence about glutathione.
Why is gamma-glutamyltransferase linked to glutathione?▾
Gamma-glutamyltransferase acts on extracellular glutathione, which is why the enzyme is sometimes described as an oxidative stress marker. A 2016 review examined it as a measure with multiple drivers and debated clinical significance rather than as a direct indicator of glutathione status (PMID 27512925). A laboratory value therefore does not reveal how much glutathione a liver contains.
What is the regulatory status of glutathione in the United States?▾
Oral glutathione is sold as a dietary supplement. The FDA does not approve dietary supplements for efficacy before they reach the market, so availability implies no agency finding of benefit for the liver. Prescription medicines and intravenous administration are separate categories. No glutathione product has FDA approval for skin lightening. Personal questions belong with a licensed physician.
How does selenium relate to glutathione in liver research?▾
Glutathione peroxidases are selenium-dependent enzymes, so selenium status intersects with this antioxidant system. A 2020 review examined selenium and selenoprotein P specifically in non-alcoholic fatty liver disease (PMID 31493247). That review describes a nutritional and biochemical relationship; it does not show that supplementing any single nutrient changes liver disease outcomes in people.
What do glutathione S-transferase findings mean for liver disease?▾
A 2022 report described hepatocyte glutathione S-transferase mu 2 as suppressing ASK1 signalling and limiting non-alcoholic steatohepatitis in experimental models (PMID 34656650). That places a glutathione-dependent enzyme inside a stress-kinase pathway. Mechanistic findings of this type describe biology in models and do not demonstrate that a supplement produces the same effect in humans.
Can animal studies of liver antioxidants be applied to people?▾
Researchers reported that zingerone improved features of non-alcoholic fatty liver disease in rats through AMPK activation (PMID 35338494). Rodent findings describe a mechanism in an animal model under controlled conditions. Human liver disease differs in cause, duration and comorbidity, and fibrosis staging in people uses separate methods described in a 2024 review chapter (PMID 39287864).
Why do observational biomarker studies not settle the question?▾
A 2022 case-cohort analysis examined adiposity and metabolomic biomarkers in relation to incident non-alcoholic fatty liver disease (PMID 34902008). Observational designs identify associations and cannot show that altering a marker changes disease risk. Multi-ingredient studies add a different limitation, since an acute comparison of NAD+ precursors inside a combination product cannot isolate one component (PMID 37271226).
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education. It is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.